Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future hepatitis C therapies.

Roberto J Firpi1, David R Nelson

  • 1Section of Hepatobiliary Diseases and Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida 32610-0214, USA. firpirj@medicine.ufl.edu

Archives of Medical Research
|July 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis.

BMC public health·2025
Same author

Lineage-specific patterns in the Moraceae family allow identification of convergent P450 enzymes involved in furanocoumarin biosynthesis.

The New phytologist·2025
Same author

Transcriptomic resources for Bagrada hilaris (Burmeister), a widespread invasive pest of Brassicales.

PloS one·2024
Same author

Genomic, transcriptomic, and metabolomic analyses reveal convergent evolution of oxime biosynthesis in Darwin's orchid.

Molecular plant·2024
Same author

Sequence diversity in the monooxygenases involved in oxime production in plant defense and signaling: a conservative revision in the nomenclature of the highly complex CYP79 family.

The Plant journal : for cell and molecular biology·2024
Same author

Cytochromes P450 evolution in the plant terrestrialization context.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2024
Same journal

Financial Costs of Tobacco-Attributable Temporary Sick Leave in Social Security Systems: The Case of Mexico, 2010-2022.

Archives of medical research·2026
Same journal

Access to Medicines for Rare Diseases in Brazil.

Archives of medical research·2026
Same journal

Perceptions, Behaviors, and Barriers among Adolescents Living with Obesity, Caregivers, and Healthcare Professionals in Mexico: ACTION Teens Study.

Archives of medical research·2026
Same journal

Clinical and Genomic Characteristics of Mexican Patients with Early Onset Gastric Adenocarcinoma.

Archives of medical research·2026
Same journal

Polymeric Immunoglobulin Receptor-Lateral Flow Immunochromatographic Strip for Cholangiocarcinoma Screening.

Archives of medical research·2026
Same journal

Protective Effects of Glycyl-Glutamine Dipeptide on In Vitro Brain Ischemia Reperfusion Model and the Role of Sigma-1 Receptors.

Archives of medical research·2026
See all related articles

Hepatitis C treatment has improved, but current options have drawbacks. Future hepatitis C therapies promise better outcomes and tolerability, addressing unmet clinical needs.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Chronic hepatitis C (HCV) treatment has advanced significantly over 15 years.
  • Understanding viral kinetics and molecular virology improved eradication rates to 50%.

Purpose of the Study:

  • To review current hepatitis C therapies.
  • To highlight recent advances in novel hepatitis C treatment strategies.

Main Methods:

  • Literature review of current and emerging hepatitis C treatments.
  • Analysis of viral kinetics and molecular virology in hepatitis C.

Main Results:

  • Current hepatitis C therapies are suboptimal, causing side effects and poor tolerability.
  • Significant progress in understanding hepatitis C has led to improved, though not ideal, treatment outcomes.

Related Experiment Videos

Conclusions:

  • There is a critical need for improved hepatitis C treatment strategies.
  • The next 5-10 years will likely see dramatic changes in hepatitis C management due to ongoing research.